Skip to Content
Merck
  • Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.

Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.

Journal of medicinal chemistry (2006-12-08)
Artem Cherkasov, Fuqiang Ban, Yvonne Li, Magid Fallahi, Geoffrey L Hammond
ABSTRACT

A combination of protein-ligand docking and ligand-based QSAR approaches has been elaborated, aiming to speed-up the process of virtual screening. In particular, this approach utilizes docking scores generated for already processed compounds to build predictive QSAR models that, in turn, assess hypothetical target binding affinities for yet undocked entries. The "progressive docking" has been tested on drug-like substances from the NCI database that have been docked into several unrelated targets, including human sex hormone binding globulin (SHBG), carbonic anhydrase, corticosteroid-binding globulin, SARS 3C-like protease, and HIV1 reverse transcriptase. We demonstrate that progressive docking can reduce the amount of computations 1.2- to 2.6-fold (when compared to traditional docking), while maintaining 80-99% hit recovery rates. This progressive-docking procedure, therefore, substantially accelerates high throughput screening, especially when using high accuracy (slower) docking approaches and large-sized datasets, and has allowed us to identify several novel potent nonsteroidal SHBG ligands.

MATERIALS
Product Number
Brand
Product Description

Supelco
Testosterone, VETRANAL®, analytical standard
Sigma-Aldrich
β-Estradiol, powder, γ-irradiated, suitable for cell culture
Sigma-Aldrich
β-Estradiol, BioReagent, powder, suitable for cell culture
Sigma-Aldrich
β-Estradiol, analytical standard
Sigma-Aldrich
Estradiol, meets USP testing specifications
Supelco
Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard
Sigma-Aldrich
β-Estradiol, ≥98%